Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone-Reference-Cited by-同舟云学术

Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone

Published:2019-10-18 Issue:20 Volume:3 Page:3002-3009
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Kastritis Efstathios¹^ORCID,Dialoupi Ioanna¹,Gavriatopoulou Maria¹,Roussou Maria¹,Kanellias Nikolaos¹,Fotiou Despina¹,Ntanasis-Stathopoulos Ioannis¹^ORCID,Papadopoulou Elektra¹,Ziogas Dimitrios C.¹^ORCID,Stamatelopoulos Kimon¹^ORCID,Manios Efstathios¹,Ntalianis Argyrios¹,Eleutherakis-Papaiakovou Evangelos¹^ORCID,Papanikolaou Asimina²,Migkou Magdalini¹,Papanota Aristea-Maria¹,Gakiopoulou Harikleia³,Psimenou Erasmia¹,Tselegkidi Maria Irini¹,Tsitsilonis Ourania⁴,Kostopoulos Ioannis⁴^ORCID,Terpos Evangelos¹^ORCID,Dimopoulos Meletios A.¹^ORCID

Affiliation:

1. Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece;

2. Department of Haemopathology, “Evangelismos” Hospital, Athens, Greece; and

3. 1st Department of Pathology and

4. Department of Biology, School of Science, National and Kapodistrian University of Athens, Athens, Greece

Abstract

Key Points Bortezomib with dexamethasone and low-dose lenalidomide is an active therapy for previously untreated patients with AL amyloidosis. VRD can induce MRD-negative responses, but nonhematologic toxicity may be significant in patients with advanced disease.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/3/20/3002/1257640/advancesadv2019000147.pdf

Reference46 articles.

1. Systemic amyloidosis;Wechalekar;Lancet,2016

2. Recent advances in the management of AL Amyloidosis;Kastritis;Br J Haematol,2016

3. Systemic immunoglobulin light chain amyloidosis;Merlini;Nat Rev Dis Primers,2018

4. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis;Mikhael;Blood,2012

5. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis;Palladini;Blood,2015

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current progress in CAR-based therapy for kidney disease;Frontiers in Immunology;2024-08-20

2. AL amyloidosis: an overview on diagnosis, staging system, and treatment;Frontiers in Hematology;2024-05-08

3. The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis;Leukemia & Lymphoma;2024-04-11

4. Morphological profiling in human neural progenitor cells classifies hits in a pilot drug screen for Alzheimer’s disease;Brain Communications;2024

5. Treatment of Amyloid Light-Chain Amyloidosis;Cardiac Amyloidosis;2024